US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

89.33

-1.0300-1.14%

Post-market: 89.330.00000.00%19:30 EDT

Volume:1.91M

Turnover:169.53M

Market Cap:7.88B

PE:-44.44

High:90.97

Open:89.15

Low:86.40

Close:90.36

52wk High:110.18

52wk Low:14.51

Shares:88.17M

Float Shares:80.98M

Volume Ratio:1.35

T/O Rate:2.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0100

EPS(LYR):-1.9755

ROE:-22.98%

ROA:-19.81%

PB:8.25

PE(LYR):-45.22

Loading ...

Overview Company News Filings

Spyre Therapeutics Exec Says Spy001 Monotherapy Matched or Exceeded Efficacy Seen With Johnson & Johnson's Combination on Some Endpoints in Mid-Stage Study - Conf Call

THOMSON REUTERS

Spyre Shares up 23% Premarket After Co Says Inflammatory Bowel Drug Reduces Disease Activity in Mid-Stage Study

THOMSON REUTERS

Spyre Therapeutics Sees Positive Results From Ulcerative Colitis Trial

Spyre says SPY001 meets primary endpoint in Phase 2 ulcerative colitis trial

BRIEF-Spyre Therapeutics Reports Positive 12-Week Phase 2 Data For SPY001 In Skyline Trial

Spyre Announces Potential Best-in-Class Spy001 Part a Induction Results From Skyline Trial in Moderate-to-Severe Ulcerative Colitis Patients

THOMSON REUTERS

Spyre Therapeutics: Secondary Endpoints Included Clinical Remission by Modified Mayo Score of 40% & Endoscopic Improvement of 51%

THOMSON REUTERS

Spyre's inflammatory bowel drug reduces disease activity in mid-stage study

Spyre Therapeutics: There Were Six Subjects With Treatment-Emergent Adverse Events During Induction Treatment Period

THOMSON REUTERS

Spyre Therapeutics: Announces Positive 12-Week Induction Data From Part a of Phase 2 Skyline Trial of Spy001

THOMSON REUTERS

Spyre Therapeutics: Spy001 Met Primary Endpoint Showing Statistically Significant Reduction in Rhi Score of 9.2 Points

THOMSON REUTERS

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Spyre to report SKYLINE trial topline induction results for SPY001 in ulcerative colitis

Spyre Therapeutics announces annual shareholder meeting webcast

Assessing Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Progress And Strong Share Price Momentum

Simply Wall St.

Spyre CEO Cameron Turtle disposes of $0.7 million common shares

Spyre Therapeutics CMO Sheldon Sloan disposes of common shares worth 0.4 million

Spyre CFO Scott Burrows disposes Spyre Therapeutics common stock worth $369,004.60

Spyre Therapeutics grants inducement stock options for 70,200 shares to five hires

Spyre Therapeutics Announces Grants of Inducement Awards

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SYRE/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":89.33,"timestamp":1788206400000,"preClose":90.36,"halted":0,"volume":1913157,"hourTrading":{"tag":"盘后","latestPrice":89.33,"preClose":89.33,"latestTime":"19:30 EDT","volume":252023,"amount":22513171.04498,"timestamp":1788219002481,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01139884904825145,"floatShares":80977000,"shares":88173800,"eps":-2.009956,"marketStatus":"Not Yet Opened","change":-1.03,"latestTime":"08-31 16:00:00 EDT","open":89.15,"high":90.965,"low":86.4,"amount":169534790.1864,"amplitude":0.05052,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.009956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":90.36,"preHourTrading":{"tag":"盘前","latestPrice":88.13,"preClose":90.36,"latestTime":"09:29 EDT","volume":763,"amount":68221.45519000001,"timestamp":1788182999999,"change":-2.23,"changeRate":-0.024679,"amplitude":0.02479},"postHourTrading":{"tag":"盘后","latestPrice":89.33,"preClose":89.33,"latestTime":"19:30 EDT","volume":252023,"amount":22513171.04498,"timestamp":1788219002481,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.345119,"impliedVol":0.8996,"impliedVolPercentile":0.7729},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":80977000,"roa":"-19.81%","roe":"-22.98%","lyrEps":-1.975476,"volumeRatio":1.345119,"shares":88173800,"dividePrice":0,"high":90.965,"amplitude":0.05052,"preClose":90.36,"low":86.4,"week52Low":14.505,"pbRate":"8.25","week52High":110.175,"institutionHeld":0,"latestPrice":89.33,"eps":-2.009956,"divideRate":0,"volume":1913157,"delay":0,"ttmEps":-2.009956,"open":89.15,"prevYearClose":32.76,"prevWeekClose":90.36,"prevMonthClose":98.33,"prevQuarterClose":88.78,"fiveDayClose":106.65,"twentyDayClose":94.93,"sixtyDayClose":78.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"SYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2026-05-05","symbol":"SYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2026-02-19","symbol":"SYRE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-04","symbol":"SYRE","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5294,"buy":0.4118,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4118,"analysts":17,"updateTime":1785470400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2026-08-28","current":-44.443759,"percent":0.049635,"low":-53.677585,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"high":-0.199399,"avg":-12.382014,"sd":13.405227,"marketCap":8254386729},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-31","current":-9.090497,"twenty":-6.704732,"median":-4.696933,"eighty":-3.700564,"marketCap":1880042140},{"date":"2025-11-07","current":-11.662076,"twenty":-6.790267,"median":-4.714264,"eighty":-3.706047,"marketCap":1737287790},{"date":"2025-11-14","current":-11.787083,"twenty":-6.900444,"median":-4.731283,"eighty":-3.707046,"marketCap":1755909901},{"date":"2025-11-21","current":-12.224606,"twenty":-6.988263,"median":-4.745208,"eighty":-3.707046,"marketCap":1821087291},{"date":"2025-11-28","current":-15.625828,"twenty":-7.239349,"median":-4.751954,"eighty":-3.713244,"marketCap":2327763900},{"date":"2025-12-05","current":-17.454049,"twenty":-7.296115,"median":-4.772037,"eighty":-3.728167,"marketCap":2600112276},{"date":"2025-12-12","current":-17.896781,"twenty":-7.380142,"median":-4.779357,"eighty":-3.742192,"marketCap":2666065586},{"date":"2025-12-19","current":-17.433215,"twenty":-7.489402,"median":-4.800924,"eighty":-3.751648,"marketCap":2597008591},{"date":"2025-12-26","current":-17.214453,"twenty":-7.525937,"median":-4.815979,"eighty":-3.763383,"marketCap":2564419896},{"date":"2026-01-02","current":-17.063404,"twenty":-7.573901,"median":-4.841253,"eighty":-3.771122,"marketCap":2541918178},{"date":"2026-01-09","current":-15.698748,"twenty":-7.596248,"median":-4.85056,"eighty":-3.792677,"marketCap":2338626798},{"date":"2026-01-16","current":-17.235288,"twenty":-7.641035,"median":-4.868549,"eighty":-3.827277,"marketCap":2567523581},{"date":"2026-01-23","current":-17.756149,"twenty":-7.65516,"median":-4.878917,"eighty":-3.836222,"marketCap":2645115711},{"date":"2026-01-30","current":-17.49051,"twenty":-7.716495,"median":-4.891913,"eighty":-3.850233,"marketCap":2605543725},{"date":"2026-02-06","current":-17.157159,"twenty":-7.797537,"median":-4.900675,"eighty":-3.876725,"marketCap":2555884762},{"date":"2026-02-13","current":-18.146794,"twenty":-7.885881,"median":-4.903471,"eighty":-3.891573,"marketCap":2703309809},{"date":"2026-02-20","current":-23.527864,"twenty":-7.934432,"median":-4.916265,"eighty":-3.909092,"marketCap":3504922382},{"date":"2026-02-27","current":-21.83597,"twenty":-8.038472,"median":-4.931737,"eighty":-3.918816,"marketCap":3389008076},{"date":"2026-03-06","current":-20.540487,"twenty":-8.323214,"median":-4.953617,"eighty":-3.922049,"marketCap":3187945256},{"date":"2026-03-13","current":-20.449399,"twenty":-8.618907,"median":-4.962688,"eighty":-3.925813,"marketCap":3173808027},{"date":"2026-03-20","current":-21.41089,"twenty":-8.906386,"median":-4.973688,"eighty":-3.927002,"marketCap":3323034338},{"date":"2026-03-27","current":-24.0474,"twenty":-8.969358,"median":-4.994463,"eighty":-3.931452,"marketCap":3732228593},{"date":"2026-04-02","current":-24.745746,"twenty":-9.172768,"median":-5.075907,"eighty":-3.931939,"marketCap":3840614019},{"date":"2026-04-10","current":-26.198104,"twenty":-9.23713,"median":-5.085831,"eighty":-3.944911,"marketCap":4066024290},{"date":"2026-04-17","current":-38.738151,"twenty":-9.365612,"median":-5.125877,"eighty":-3.981637,"marketCap":6012277252},{"date":"2026-04-24","current":-38.48249,"twenty":-9.54815,"median":-5.141783,"eighty":-3.990939,"marketCap":5972597947},{"date":"2026-05-01","current":-41.378125,"twenty":-11.574571,"median":-5.163524,"eighty":-3.996385,"marketCap":6422009203},{"date":"2026-05-08","current":-35.378246,"twenty":-11.912235,"median":-5.194337,"eighty":-4.002987,"marketCap":6348095594},{"date":"2026-05-15","current":-36.612371,"twenty":-12.227731,"median":-5.199556,"eighty":-4.01025,"marketCap":6569540789},{"date":"2026-05-22","current":-35.96869,"twenty":-12.66317,"median":-5.24323,"eighty":-4.012918,"marketCap":6454041922},{"date":"2026-05-29","current":-34.899115,"twenty":-14.84662,"median":-5.263514,"eighty":-4.014565,"marketCap":6262122753},{"date":"2026-06-05","current":-37.982008,"twenty":-15.625828,"median":-5.295394,"eighty":-4.016676,"marketCap":6815301535},{"date":"2026-06-12","current":-39.0903,"twenty":-15.934177,"median":-5.346464,"eighty":-4.018572,"marketCap":7014168004},{"date":"2026-06-18","current":-42.342582,"twenty":-16.532126,"median":-5.375072,"eighty":-4.022327,"marketCap":7597741224},{"date":"2026-06-26","current":-42.913667,"twenty":-16.744637,"median":-5.470693,"eighty":-4.034149,"marketCap":7700213903},{"date":"2026-07-02","current":-43.020141,"twenty":-17.038402,"median":-5.524211,"eighty":-4.045526,"marketCap":7719318979},{"date":"2026-07-10","current":-47.79209,"twenty":-17.157159,"median":-5.623342,"eighty":-4.04736,"marketCap":8575573733},{"date":"2026-07-17","current":-46.12579,"twenty":-17.21862,"median":-5.641652,"eighty":-4.048014,"marketCap":8276581215},{"date":"2026-07-24","current":-49.002526,"twenty":-17.305083,"median":-5.684807,"eighty":-4.051257,"marketCap":8792768335},{"date":"2026-07-31","current":-49.742539,"twenty":-17.37592,"median":-5.758017,"eighty":-4.05376,"marketCap":8925552415},{"date":"2026-08-07","current":-50.967094,"twenty":-17.454049,"median":-5.886958,"eighty":-4.070861,"marketCap":9118930466},{"date":"2026-08-14","current":-50.193372,"twenty":-17.542596,"median":-5.928557,"eighty":-4.072986,"marketCap":8980497659},{"date":"2026-08-21","current":-53.120702,"twenty":-17.704063,"median":-5.957984,"eighty":-4.07743,"marketCap":9504249805},{"date":"2026-08-28","current":-46.135027,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"marketCap":8254386729}],"updateTime":1788227318899},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627458411","title":"Spyre Therapeutics Exec Says Spy001 Monotherapy Matched or Exceeded Efficacy Seen With Johnson & Johnson's Combination on Some Endpoints in Mid-Stage Study - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627458411?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:23","pubTimestamp":1776083001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1221951129.SGD","IE0002141913.USD","LU2471134879.HKD","LU1430594728.SGD","LU2129689514.USD","LU1023059063.AUD","LU1914381329.SGD","LU0114720955.EUR","SG9999002232.USD","IE000WAW04H5.SGD","BK4139","LU2471134523.USD","BK4592","LU0345769631.USD","SGXZ57979304.SGD","LU1196500208.SGD","LU0234570918.USD","LU1585245621.USD","BK4533","LU0889566641.SGD","IE00BGHQF631.EUR","LU1718418525.SGD","BK4550","BK4581","IE00BSNM7G36.USD","LU0203347892.USD","IE00B4R5TH58.HKD","LU0792757196.USD","BK4585","LU2133065610.SGD","LU0320765646.SGD","LU0882574055.USD","SYRE","IE00BFXG1179.USD","IE00B3PB1722.GBP","LU1778281490.HKD","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","JNJ","LU1674673428.USD","LU1066053197.SGD","LU2430703178.SGD","LU1121112475.USD","LU2347655156.SGD","LU1506573853.SGD","LU1059921491.USD","LU2430703251.USD","LU0683600562.USD","LU0795875169.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437031","title":"Spyre Shares up 23% Premarket After Co Says Inflammatory Bowel Drug Reduces Disease Activity in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627437031?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:40","pubTimestamp":1776080410,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W0TR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437576","title":"Spyre Therapeutics Sees Positive Results From Ulcerative Colitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437576","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627437576?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:25","pubTimestamp":1776079500,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative colitis.The clinical-stage biotechnology company said Monday it achieved positive 12-week induction data from the first part of its Phase 2 Skyline trial of SPY001.The study met its primary endpoint with a statistically significant reduction of 9.2 points from baseline at week 12 in a Robart's Histopathology Index score. Secondary endpoints included clinical remission by modified Mayo score of 40% and endoscopic improvement of 51%, Spyre said.Trading in Spyre's shares was halted ahead of the news.The company said recruitment for part A of Skyline is now closed and that enrollment is open for part B, which it said includes three monotherapy cohorts and three combination cohorts. Proof-of-concept induction data for the remaining cohorts of part A are now expected mid-2026 for SPY002 and in the third quarter for SPY003, Spyre said. Part B induction data for all cohorts re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SYRE","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627159432","title":"Spyre says SPY001 meets primary endpoint in Phase 2 ulcerative colitis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627159432","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627159432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:03","pubTimestamp":1776078185,"startTime":"0","endTime":"0","summary":"Spyre reported positive 12-week induction results already presented from Part A of Phase 2 SKYLINE trial of SPY001 in moderate-to-severe ulcerative colitis.Study met primary goal, supporting meaningful improvement in disease activity versus baseline.Secondary measures also improved, reinforcing potential for a best-in-class profile.Safety profile was consistent with anti-α4β7 class, supporting continued development.Enrollment shifted to Part B, expanding evaluation of SPY001 as monotherapy and in combination, with additional proof-of-concept readouts expected mid-2026 and Q3 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL6hYbmr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4139","SYRE","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627324864","title":"BRIEF-Spyre Therapeutics Reports Positive 12-Week Phase 2 Data For SPY001 In Skyline Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627324864","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627324864?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078003,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Reports Positive 12-Week Phase 2 Data For SPY001 In Skyline TrialApril 13  - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS: SPY001 MET PRIMARY ENDPOINT SHOWING STATISTICALLY SIGNIFICANT REDUCTION IN RHI SCORE OF 9.2 POINTSSPYRE THERAPEUTICS: ANNOUNCES POSITIVE 12-WEEK INDUCTION DATA FROM PART A OF PHASE 2 SKYLINE TRIAL OF SPY001SPYRE THERAPEUTICS: SECONDARY ENDPOINTS INCLUDED CLINICAL REMISSION BY MODIFIED MAYO SCORE OF 40% & ENDOSCOPIC IMPROVEMENT OF 51%SPYRE THERAPEUTICS: THERE WERE SIX SUBJECTS WITH TREATMENT-EMERGENT ADVERSE EVENTS DURING INDUCTION TREATMENT PERIODFurther company coverage: SYRE.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nP8N3W407Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432952","title":"Spyre Announces Potential Best-in-Class Spy001 Part a Induction Results From Skyline Trial in Moderate-to-Severe Ulcerative Colitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432952?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUABN6RC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627943233","title":"Spyre Therapeutics: Secondary Endpoints Included Clinical Remission by Modified Mayo Score of 40% & Endoscopic Improvement of 51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627943233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627943233?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nP8N3W407Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627632432","title":"Spyre's inflammatory bowel drug reduces disease activity in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627632432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627632432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":"Spyre's inflammatory bowel drug reduces disease activity in mid-stage study April 13  - Spyre Therapeutics SYRE.O said on Monday its experimental drug demonstrated a significant reduction in disease activity in a mid-stage study of patients with ulcerative colitis.The drug, SPY001, met the trial's main goal by reducing a key measure of tissue-level inflammation after 12 weeks of treatment, the drug developer said. Ulcerative colitis is a chronic inflammatory disease causing swelling and ulcers in the lining of the colon and rectum. In the study, 40% of patients achieved clinical remission and 51% showed visible improvement in intestinal tissue.SPY001 is designed to build on the activity of Takeda Pharmaceutical's 4502.T Entyvio, with a longer-lasting effect and higher induction dosing, Spyre said.Six patients reported treatment-emergent adverse events during the induction period, including one serious event unrelated to the drug. The most common side effect was back pain, reported by t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W0NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432353","title":"Spyre Therapeutics: There Were Six Subjects With Treatment-Emergent Adverse Events During Induction Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432353?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nP8N3W407Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432334","title":"Spyre Therapeutics: Announces Positive 12-Week Induction Data From Part a of Phase 2 Skyline Trial of Spy001","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432334?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nP8N3W407Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627330432","title":"Spyre Therapeutics: Spy001 Met Primary Endpoint Showing Statistically Significant Reduction in Rhi Score of 9.2 Points","url":"https://stock-news.laohu8.com/highlight/detail?id=2627330432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627330432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nP8N3W407Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627008434","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2627008434","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627008434?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:55","pubTimestamp":1776077700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nAQN2LUD9I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626711029","title":"Spyre to report SKYLINE trial topline induction results for SPY001 in ulcerative colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2626711029","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626711029?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:09","pubTimestamp":1775851752,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics scheduled release of SPY001 Part A induction topline results from SKYLINE trial in moderate-to-severely active ulcerative colitis for April 13, 2026.Data have not been presented yet; results will be discussed on conference call and webcast at 8:00 a.m. ET on April 13, 2026.Announcement did not disclose trial outcomes, focusing instead on timing of upcoming topline readout.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL7KmGdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626104891","title":"Spyre Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2626104891","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626104891?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:02","pubTimestamp":1775851370,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics schedules 2026 annual stockholder meeting for May 27, 2026 as virtual-only webcast.Ballot includes election of three Class I directors to terms ending at 2029 annual meeting.Stockholders will vote on advisory approval of named executive officer compensation.Meeting will also consider approval of amended and restated 2016 employee stock purchase plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL7MwWPs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625964793","title":"Assessing Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Progress And Strong Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625964793?lang=en_us&edition=fundamental","pubTime":"2026-04-05 23:24","pubTimestamp":1775402667,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) recently accelerated its Phase 2 SKYWAY basket trial by completing enrollment for the rheumatoid arthritis sub study of SPY072 ahead of schedule, with topline data now guided for Q3 2026.\nSee our latest analysis for Spyre Therapeutics.\nThe accelerated SKYWAY timeline comes on top of a sharp run, with Spyre Therapeutics posting a 30 day share price return of 18.51% and a 90 day share price return of 58.81%. The 1 year total shareholder return of 272.01% and 3 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/assessing-spyre-therapeutics-syre-valuation-after-accelerate","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/assessing-spyre-therapeutics-syre-valuation-after-accelerate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","SYRE","BK4139","PRGS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698202","title":"Spyre CEO Cameron Turtle disposes of $0.7 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698202?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:31","pubTimestamp":1775266278,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron sold 15,000 shares on April 1.Sales totaled about 0.7 million at weighted average prices of $49.2 and $49.92.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL7Znhxy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698274","title":"Spyre Therapeutics CMO Sheldon Sloan disposes of common shares worth 0.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698274","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698274?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266244,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Chief Medical Officer Sheldon Sloan reported sale of 7,958 shares on April 1, 2026 at USD 50.Transaction followed exercise of stock options for 7,958 shares at USD 21.66.Sloan reported 0 shares of common stock owned following transactions.Filing showed 87,542 stock options held following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL92MLgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CMO Sheldon Sloan disposes of common shares worth 0.4 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624982086","title":"Spyre CFO Scott Burrows disposes Spyre Therapeutics common stock worth $369,004.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2624982086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624982086?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266207,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CFO Scott L Burrows cut direct holdings to 97,994 shares in transactions dated April 1, 2026.Burrows sold 7,500 shares at USD 49.21 to USD 49.98 per share.He acquired 7,500 shares at USD 14.5 per share through an option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL162p2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624661062","title":"Spyre Therapeutics grants inducement stock options for 70,200 shares to five hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624661062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624661062?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:01","pubTimestamp":1775246485,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics granted stock options covering 70,200 shares to five non-executive employees under its 2018 Equity Inducement Plan.Options carry a 10-year term with an exercise price of $48.90, based on April 1, 2026 close.Vesting starts with 25% on first anniversary of each employee’s start date.Remaining awards vest monthly at 1/48 thereafter, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLb82G88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SYRE","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624646586","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2624646586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624646586?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:01","pubTimestamp":1775246460,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3268133/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":175,"code":"91000000","status":"200"}]}}